The Latest in Prolonged Intermittent Kidney Replacement Therapy (PIKRT)

Learn how hybrid Kidney Replacement Therapies (KRT), such as PIKRT, can benefit you, your patients and your hospital.

Dr. Anitha Vijayan*, Medical Director of Acute Dialysis Services at Barnes-Jewish Hospital in St. Louis, will review Prolonged Intermittent Kidney Replacement Therapy (PIKRT) as a hybrid KRT option; including an update on COVID-19, patient selection, current guidelines and clinical evidence demonstrating benefits and challenges of PIKRT.



Anitha Vijayan, MD
Medical Director of Acute Dialysis Services, Barnes-Jewish Hospital
St. Louis, MO

Dr. Anitha Vijayan received her medical degree from the University of the West Indies. She completed her residency in Internal Medicine at St. Luke’s hospital in Chesterfield, MO and her Nephrology fellowship at Washington University. Dr. Vijayan currently serves as Medical Director of Acute Dialysis Services at Barnes-Jewish Hospital, the premier teaching institution of the Washington University. Her clinical expertise and research has been primarily dedicated to improving outcomes in patients with acute kidney injury.  She has published widely in the area of biomarkers for early diagnosis and renal replacement therapy in AKI. In addition to her expertise in AKI, Dr. Vijayan has also been involved in infection prevention and currently chairs a workgroup as part of the ASN-NTDS committee which is focused on reducing infections in hemodialysis patients.  She holds several administrative roles at the university and the hospital, including being a member of the Medical School Admissions Committee, Faculty Practice Plan and the Pharmacy and Therapeutics Committee.  She is also a member of American Society of Nephrology and National Kidney Foundation.

 *Member of the NxStage Scientific Advisory Board and paid speaker for NxStage Medical, Inc.



Watch Webinar now

Complete this form to register for the webcast.



Renal replacement therapy, as with any medical therapy, is not without risks. The decision of which therapy to use should be made by the physician, based on previous experience and on the individual facts and circumstances of the patient. There is no literature demonstrating one therapy is clinically better than another.1

1. D. M. Nash, S. Przech, R. Wald, and D. O’Reilly, “Systematic review and meta-analysis of renal replacement therapy modalities for acute kidney injury in the intensive care unit,” Journal of Critical Care, vol. 41, pp. 138–144, 2017.

CAUTION: Federal law restricts this device to sale by or on the order of a physician. 

© 2021 Fresenius Medical Care. All Rights Reserved. Fresenius Medical Care, the triangle logo, and NxStage are trademarks of Fresenius Medical Care Holdings, Inc. or its affiliated companies. All other trademarks are the property of their respective owners. P/N 104736-01 REV B 10/2021 / APM4255 REV B